Multiple Myeloma Clinical Trials in Omaha, Nebraska

13 studies are recruiting for multiple myeloma in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

   This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Institute, Omaha, Nebraska

   Locations

   24 in total

   Run by

   Heidelberg Pharma AG

   See if you can join NCT04879043 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

4. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

5. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

   Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

   Stage

   Not phased

   Ages

   19 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT04898790 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   21 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

7. Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

   Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell en…

   Stage

   Not phased

   Ages

   19 and older

   Site

   Unversity of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT05135351 on ClinicalTrials.gov

8. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

   The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University Of Nebraska Medical Center, Omaha, Nebraska

   Locations

   19 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06121843 on ClinicalTrials.gov

9. Selinexor and Backbone Treatments of Multiple Myeloma Patients

   This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to b…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   25 in total

   Run by

   Karyopharm Therapeutics Inc

   See if you can join NCT02343042 on ClinicalTrials.gov

10. A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha, Nebraska

    Locations

    46 in total

    Run by

    AbbVie

    See if you can join NCT05650632 on ClinicalTrials.gov

11. Halt Aging in Survivors of Blood Cancers

    Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting th…

    Stage

    Not phased

    Ages

    50 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT07292272 on ClinicalTrials.gov

12. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage

    Not phased

    Ages

    19 to 110

    Site

    Methodist Estabrook Cancer Center, Omaha, Nebraska

    Locations

    42 in total

    Run by

    University of Nebraska

    See if you can join NCT02012699 on ClinicalTrials.gov

13. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Nebraska Cancer Specialists, Omaha, Nebraska

    Locations

    39 in total

    Run by

    CellCentric Ltd.

    See if you can join NCT04068597 on ClinicalTrials.gov